Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Tumour necrosis factor alpha blockade and the risk of vasculitis.

Literature DB >> 17038458

Tumour necrosis factor alpha blockade and the risk of vasculitis.

M De Bandt, B Saint-Marcoux.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2006 PMID： 17038458 PMCID： PMC1798338 DOI： 10.1136/ard.2006.051888

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

9 in total

1. Etanercept and infliximab associated with cutaneous vasculitis.

Authors: M E McCain; R J Quinet; W E Davis
Journal: Rheumatology (Oxford) Date: 2002-01 Impact factor: 7.580

2. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis.

Authors: J-M Berthelot; J Glemarec; Y Maugars; A Prost
Journal: Rheumatology (Oxford) Date: 2002-06 Impact factor: 7.580

3. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis.

Authors: P A Livermore; K J Murray
Journal: Rheumatology (Oxford) Date: 2002-12 Impact factor: 7.580

4. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.

Authors: Christian Hubert Roux; Olivier Brocq; Véronique Albert C Breuil; Liana Euller-Ziegler
Journal: Joint Bone Spine Date: 2004-09 Impact factor: 4.929

5. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Authors: Adam Mor; Clifton O Bingham; Clifton Bingham; Laura Barisoni; Eileen Lydon; H Michael Belmont
Journal: J Rheumatol Date: 2005-04 Impact factor: 4.666

6. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab.

Authors: Laura McIlwain; John D Carter; Syed Bin-Sagheer; Frank B Vasey; Juergen Nord
Journal: J Clin Gastroenterol Date: 2003 May-Jun Impact factor: 3.062

7. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.

Authors: Pascal Richette; Philippe Dieudé; Joël Damiano; Frédéric Lioté; Philippe Orcel; Thomas Bardin
Journal: J Rheumatol Date: 2004-10 Impact factor: 4.666

8. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

Authors: Niveditha Mohan; Evelyne T Edwards; Thomas R Cupps; Nancy Slifman; Jong-Hoon Lee; Jeffrey N Siegel; M Miles Braun
Journal: J Rheumatol Date: 2004-10 Impact factor: 4.666

9. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors: Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal: J Rheumatol Date: 2003-10 Impact factor: 4.666

9 in total

7 in total

7. Adalimumab (TNF α Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient.

Authors: S S Wei; R Sinniah
Journal: Case Rep Nephrol Date: 2013-07-24

7 in total

Tumour necrosis factor alpha blockade and the risk of vasculitis.

1. Etanercept and infliximab associated with cutaneous vasculitis.

2. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis.

3. Anti-tumour necrosis factor therapy associated with cutaneous vasculitis.

4. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis.

5. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

6. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab.

7. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.

8. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

9. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Review 1. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis.

Review 2. Anti-inflammatory and proresolving lipid mediators.

3. Etanercept treatment-related c-ANCA-associated large vessel vasculitis.

4. Multi-Organ Infarction in a Patient Receiving Infliximab.

Review 5. A Spotlight on Drug-Induced Vasculitis.

6. Appearance of ANCA - associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment.

7. Adalimumab (TNF α Inhibitor) Therapy Exacerbates IgA Glomerulonephritis Acute Renal Injury and Induces Lupus Autoantibodies in a Psoriasis Patient.